Skip to main content
. 2019 Apr 17;2019(4):CD008123. doi: 10.1002/14651858.CD008123.pub4

Analysis 1.3.

Analysis 1.3

Comparison 1 Human‐derived botulinum immune globulin intravenous, Outcome 3 Death from any cause occurring within 12 weeks of randomization or the beginning of treatment.